U
URGN
Urogen Pharma
18.88
0.08+0.43%After Hours: 19.28 +0.40 +2.12%18:28 09/05 EDT
OPEN/PREV CLOSE19.03/18.80
TODAY RANGE18.58-19.32
VOL1.03M
MARKET CAP873.47M
52 WEEK RANGE3.420-21.02
AVG VOL (3M)2.27M
% TURNOVER2.22%
TURNOVER--
P/E (TTM)-5.9645
% RANGE3.94%
EPS(TTM)-3.1654
P/E(FORWARD)-5.9747
P/B-9.3410
BVPS-2.0212
DIVIDEND--
P/S8.82
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP795.17M
SHARES OUTSTANDING46.26M
NEXT EARNINGS11/04-11/10
FREE FLOAT42.12M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/29 10:57
Piper Sandler Remains a Buy on Urogen Pharma (URGN)
TipRanks·08/27 21:00
UroGen Pharma Shareholders Approve Key Proposals at Meeting
Seeking Alpha·08/19 18:46
Summit draws Neutral view on risk/reward setup as Piper initiates biotech cancer names
Dow Jones·08/19 12:14
UroGen Pharma Initiated at Overweight by Piper Sandler
Dow Jones·08/19 12:14
UroGen Pharma Price Target Announced at $36.00/Share by Piper Sandler
TipRanks·08/19 10:30
Piper starts ‘underestimated’ UroGen Pharma with an Overweight
TipRanks·08/19 07:55
Urogen Pharma (URGN) Receives a New Rating from Guggenheim
TipRanks·08/18 20:40
UroGen Pharma initiated with an Overweight at Piper Sandler
Seeking Alpha·08/18 19:34
UroGen Pharma: Targeting Profits In 2027
TipRanks·08/14 11:15
Urogen Pharma (URGN) Receives a Buy from TD Cowen
TipRanks·08/14 02:02
Top Executive Sells Thousands of Urogen Pharma Shares!
TipRanks·08/13 01:44
UroGen Pharma’s Earnings Call: Achievements and Challenges
Dow Jones·08/11 10:45
UroGen Pharma Price Target Cut to $40.00/Share From $50.00 by HC Wainwright & Co.
Dow Jones·08/11 10:45
UroGen Pharma Is Maintained at Buy by HC Wainwright & Co.
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.